Cell Biosciences Boosts F Round, Buys Brightwell

Xconomy San Francisco — 

Santa Clara, CA-based Cell Biosciences, the life sciences instrument maker that raised $20 million in Series F funding last fall, said yesterday that it has added a $13 million second tranche to the round and used some of the money to acquire Brightwell Technologies, an Ottawa, Ontari0-based maker of protein analysis tools. Essex Woodlands Health Ventures led the second tranche, which was joined by existing investors Novo A/S, Domain Associates, Latterell Venture Partners, Royal Bank of Canada, The Vertical Group, and Lansing Brown Investments.